What is CONTINUUMRX?
ContinuumRx specializes in providing comprehensive home and site-based infusion therapies and services, designed to support patient care and recovery. With over two decades of experience, the company collaborates with healthcare systems to optimize post-acute care coordination and management. Their service portfolio includes critical treatments such as antibiotic therapy, enteral and parenteral nutrition, IVIG therapy, heart failure therapy, and biologic therapies. ContinuumRx's commitment to high-quality patient care is validated by its accreditation from the Accreditation Commission for Health Care (ACHC). The company's focus on enhancing patient outcomes and streamlining healthcare delivery positions it as a key player in the evolving landscape of home healthcare solutions.
How much funding has CONTINUUMRX raised?
CONTINUUMRX has raised a total of $21.5M across 3 funding rounds:
Unspecified
$7M
Private Equity
$13.5M
Debt
$1M
Unspecified (2012): $7M with participation from Stonehenge Capital, Health Enterprise Partners, Redmont Venture Partners, and Mitsui & Co
Private Equity (2015): $13.5M led by NewSpring Capital
Debt (2020): $1M supported by PPP
Key Investors in CONTINUUMRX
Stonehenge Capital
Stonehenge Capital is a tax-credit service, venture capital, and investment firm established in 1999, likely focusing on strategic growth investments.
Health Enterprise Partners
Health Enterprise Partners is a venture capital firm that partners with organizations transforming healthcare delivery, known for its management-focused approach and deep industry knowledge.
Redmont Venture Partners
Redmont Venture Partners, previously Bonaventure Capital, is a strategic investment firm providing capital and strategic support to visionary founders, with a focus on companies addressing real-world challenges.
What's next for CONTINUUMRX?
The recent major strategic investment in ContinuumRx signals a pivotal phase for the company, likely enabling further expansion of its service lines and geographic footprint. This capital infusion is expected to bolster its partnerships with healthcare systems, enhancing the coordination and management of post-acute care. Strategic backing at this enterprise level suggests a focus on scaling operations, potentially through technological advancements in service delivery or acquisitions to broaden its therapeutic offerings. ContinuumRx is poised to leverage this financing to solidify its market leadership and continue its mission of delivering high-quality, patient-centered infusion therapies.
See full CONTINUUMRX company page
